title: [Compound nylestriol tablet to prevent bone loss in osteoporotic rats].
abstract: OBJECTIVE
  To investigate the effects of compound nylestriol tablet (CNT), containing nylestriol and levonorgestrel with a ratio of 1:0.3) and its components on the osteoporotic rat model induced by retinoic acid (RA) and ovariectomy (OVX).
  
  
  METHODS
  We randomly divided 144 female SD rats (aged 7-month-old) into 12 groups (12 in each). In addition, 120 female SD rats aged 4-month were randomly divided into 10 groups (10 in each). Three dosage levels of CNT (0.039, 0.117 and 0.39 mg/kg body weight, daily), nylestriol (NYL, 0.30, 0.09 and 0.03 mg/kg body weight, daily) and levonorgestrel (LEV, 0.09, 0.027 and 0.009 mg/kg body weight, daily) were designed to prevent the bone loss of the osteoporotic rat model induced by RA and OVX respectively. Serum total calcium (Ca), phosphate (Pi), ALP, triglyceride (TG), total cholesterol (TC), HDL-C, total body BMD, isolated left femoral BMD and femoral Ca, and Pi after ashing were determined.
  
  
  RESULTS
  Osteoporotic models could be induced by RA (70 mg/kg body weightdaily given intragastrically for 14 days) or by ovariectomy; CNT and its components had the preventive effects on bone loss in both models; The preventive effect of CNT was dose-dependent and stronger than its components; Many observed markers showed us the levels of high and moderate CNT given to be the strongest, corresponding to an optimal choice of the moderate dose CNT about one tablet per week in adult women.
  
  
  CONCLUSIONS
  CNT therapy can prevent the bone loss of RA-induced and OVX-induced osteoporotic rats, and its therapeutic and preventive effect is better than its components used alone.
authors.affiliation: Insititute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China.
authors.forename: Shi-Ping
authors.initials: SP
authors.lastname: Liu
authors.forename: Er-Yuan
authors.initials: EY
authors.lastname: Liao
authors.forename: Xian-Ping
authors.initials: XP
authors.lastname: Wu
authors.forename: Xiang-Hang
authors.initials: XH
authors.lastname: Luo
authors.forename: Huan-De
authors.initials: HD
authors.lastname: Li
authors.forename: Ze-Neng
authors.initials: ZN
authors.lastname: Chen
authors.forename: Ru-Chun
authors.initials: RC
authors.lastname: Dai
authors.forename: Rui-Yuan
authors.initials: RY
authors.lastname: Sun
authors.forename: Xi-Jiu
authors.initials: XJ
authors.lastname: Liu
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D002118:Calcium / Q000097:blood; D004338:Drug Combinations; D005260:Female; D016912:Levonorgestrel / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D010052:Ovariectomy; D010758:Phosphorus / Q000097:blood; D011800:Quinestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013607:Tablets; D014212:Tretinoin
chemical_list: D004338:Drug Combinations; D013607:Tablets; D010758:Phosphorus; D014212:Tretinoin; D016912:Levonorgestrel; C010722:nylestriol; D000469:Alkaline Phosphatase; D011800:Quinestrol; D002118:Calcium